POM121L12: A Potential Drug Target and Biomarker (G285877)

Target Name: POM121L12

NCBI ID: G285877

POM121L12

Other Name(s): POM121 membrane glycoprotein-like 12 | POM121-like protein 12 | P1L12_HUMAN | POM121 transmembrane nucleoporin like 12

POM121L12: A Potential Drug Target and Biomarker

POM121L12 is a protein that falls under the category of membrane glycoproteins, which are a type of protein that is expressed in the cell membrane and play a significant role in various physiological processes. The protein is derived from the POM1 gene, which encodes a protein with potential drug targets and biomarkers.

The POM1 gene is located on chromosome 16, specifically at position 121. This gene has four exons, which code for the POM1 protein. The first exon encodes the amino acid sequence that is specific to the POM1 protein, while the second exon encodes a signal peptide that is removed from the protein after translation. The third and fourth exons encode the amino acids that form the N-terminus and C-terminus of the protein, respectively.

POM121L12 is a 12-kDa protein that is expressed in various tissues and cells, including liver, pancreas, and muscle. The protein is localized to the endoplasmic reticulum (ER) and is predominantly expressed in the peribodies, which are the proteinaceous structures that cover the surface of the endoplasmic reticulum.

Several studies have identified POM121L12 as a potential drug target and biomarker. The POM121L12 protein is known to interact with several drug molecules, including inhibitors of the enzyme tyrosine kinase, which is involved in the signaling pathway for many cellular processes. These interactions suggest that POM121L12 may be a target for drugs that are designed to inhibit the activity of tyrosine kinases.

In addition to its potential as a drug target, POM121L12 has also been identified as a potential biomarker for a number of diseases. For example, the POM121L12 protein has been shown to be expressed in a variety of cancer types, including breast, ovarian, and colorectal cancer. This suggests that POM121L12 may be a useful biomarker for these cancers.

Furthermore, several studies have shown that POM121L12 is involved in several physiological processes that are important for human health. For example, the POM121L12 protein is involved in the regulation of cell adhesion, which is important for the development and maintenance of tissues and organs. In addition, the protein is involved in the regulation of inflammation, which is important for maintaining tissue homeostasis and preventing disease.

Given the potential drug target and biomarker properties of POM121L12, researchers are actively working to develop new treatments for a variety of diseases. For example, several studies are being conducted to investigate the potential benefits of drugs that target the POM121L12 protein. These studies are providing valuable insights into the biology of POM121L12 and its potential as a drug and biomarker.

In conclusion, POM121L12 is a protein that has the potential to be a drug target and biomarker. Its interaction with drug molecules and its involvement in several physiological processes make it an attractive target for researchers who are working to develop new treatments for a variety of diseases. Further research is needed to fully understand the biology of POM121L12 and its potential as a drug and biomarker.

Protein Name: POM121 Transmembrane Nucleoporin Like 12

The "POM121L12 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about POM121L12 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets